A newly published article in JAMA Oncology has now suggested that adding a statin to a patient’s treatment regimen at initiation of androgen deprivation therapy (ADT) may significantly impact time to disease progression among men diagnosed with progressive, hormone-sensitive prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, advanced, androgen, deprivation, hormone-sensitive, progressive, statin | 3 Comments »
We still have very little knowledge about whether early prostate cancer immunotherapy with sipuleucel-T (Provenge) or other forms of immunotherapy might be beneficial in the management of patients with high-risk prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, androgen, deprivation, progressive, sipuleucel-T | Leave a comment »
A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: progressive, Prostvac, PSA, rising, vaccine | 2 Comments »
According to a joint media release from Medivation and Astellas earlier today, the companies will soon be initiating an important and major new trial of enzalutamide in men with progressive prostate cancer after first-line therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", enzalutamide, hormone-sensitive, progressive | Leave a comment »
Let’s say you are 58 years of age, in apparently excellent health for your age, when you get diagnosed with high-risk prostate cancer, based on a Gleason score of 4 + 4 = 8, a PSA level of 3.7, and a clinical stage of T1c, with 4/12 biopsy cores positive for cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", progressive, STAMPEDE, Treatment, trial | 6 Comments »
Not so long ago (back in late 2013), Schweizer et al. reported data from a very small trial of an old drug called disulfiram (also known as Antabuse) in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, advanced, Antabuse, disulfiram, progressive, safety | 1 Comment »
An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: imaging, progressive, recurrent | 1 Comment »
A newly published, retrospective, epidemiological study has looked at the potential role of metformin the the management of prostate cancer in > 350 men already diagnosed and being treated for diabetes in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Uncategorized | Tagged: metformin, progressive, recurrent | 1 Comment »
According to a group of researchers at Queen’s University in Kingston, Ontario, a very low dose of nitroglycerin may be able to delay the progression of prostate cancer in men with a rising PSA after standard first-line treatment with radiotherapy or surgery. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: nitroglycerin, progressive, second-line | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 